Do European regulatory measures accelerate national market access in Belgium? A retrospective analysis of medicines centrally authorised between 2015 and 2020
This study shows that while European regulatory measures targeting UMNs often trigger corresponding actions in Belgium, this alignment does not necessarily shorten the time from regulatory submission to reimbursement. Lacking submission for reimbursement by pharmaceutical companies appears to be the most frequent reason for absent reimbursement in Belgium. European policy initiatives promoting timely market entry across member states could be crucial for improving patient access.
Authors
- Liese Barbier (ORCID: https://orcid.org/0000-0003-1786-2080)
- Steffen Fieuws (ORCID: https://orcid.org/0000-0002-6875-8366)
- Zilke Claessens (ORCID: https://orcid.org/0000-0003-2895-1599)
- Isabelle Huys (ORCID: https://orcid.org/0000-0002-4738-8298)
- Joël Daems
Institutions
- Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (BE)
- KU Leuven (BE)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-091361
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Bill and Melinda Gates Foundation
- University of Dundee
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- KU Leuven
- Innovative Medicines Initiative
- Institut National d'assurance Maladie-Invalidité